采纳股份 (301122.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

99.1x

Market Cap

CNY 4.77B

MomentumView details →

1D Return

−1.27%

YTD Return

+74.21%

RSI (14)

76.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

99.1x

Market Cap

CNY 4.77B

RSI (14)

76.9

MomentumView details →

1D Return

−1.27%

YTD Return

+74.21%

ProfitabilityView details →

Gross Margin

22.33%

Net Margin

2.60%

EBITDA Margin

12.77%

ROE (TTM)

0.60%

ROA (TTM)

0.49%

Asset Turnover

0.20x

GrowthView details →

Revenue YoY

+21.53%

EPS YoY

−68.37%

FCF YoY

−56.58%

Revenue CAGR 3Y

−8.49%

EPS CAGR 3Y

−69.49%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−CNY 0.03

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Capital & dividendView details →

Debt/Equity

0.09x

Current Ratio

3.28x

Quick Ratio

2.88x

Div Yield

0.09%

Div Rate

CNY 0.04

Div Growth 1Y

−84.00%

Financials snapshotView financials →

Revenue (TTM)

425.33M

Net Income (TTM)

11.05M

Op. CF (TTM)

14.25M

Next earningsOct 23, 2026 →

Latest newsMore news →

Haixiang Pharmaceutical's wholly-owned subsidiary Zhejiang Haixiang Chuannan Pharmaceutical received approval from China's National Medical Products Administration for its adenosine cyclophosphate API, packaged in 4kg/drum, with registration approved but GMP compliance check still required before domestic production and sales.10d ago

Cainiao Co., Ltd.'s wholly-owned subsidiary Jiangsu Cainiao Medical Technology Co., Ltd. received a Class III medical device registration certificate from China's National Medical Products Administration for a disposable human arterial blood sample collector, valid until August 23, 2031.10d ago

Similar companies

力星股份300421.SZ 三元生物301206.SZ 横河精密300539.SZ 科源制药301281.SZ 国光股份002749.SZ 太阳电缆002300.SZ Find similar companies →

Latest newsMore news →

Haixiang Pharmaceutical's wholly-owned subsidiary Zhejiang Haixiang Chuannan Pharmaceutical received approval from China's National Medical Products Administration for its adenosine cyclophosphate API, packaged in 4kg/drum, with registration approved but GMP compliance check still required before domestic production and sales.10d ago Cainiao Co., Ltd.'s wholly-owned subsidiary Jiangsu Cainiao Medical Technology Co., Ltd. received a Class III medical device registration certificate from China's National Medical Products Administration for a disposable human arterial blood sample collector, valid until August 23, 2031.10d ago